New York, NY -- (SBWIRE) -- 01/09/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Oi SA (ADR) (NYSE:OIBR), Array Biopharma Inc (NASDAQ:ARRY), Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX), Penn West Petroleum Ltd (USA) (NYSE:PWE)
Oi SA (ADR) (NYSE:OIBR) showed a volume of 1.54 million shares by the end of last trade whereas the average volume of the stock remained 5.75 million shares. The stock opened the session at $1.72 but then moved to $1.68. At that price, the stock showed a negative performance of -1.18%. Oi SA, formerly Brasil Telecom SA, is a Brazil-based holding company engaged in the provision of Switched Fixed-line Telephony Services (STFC) domestically and internationally. The Company operates in three segments: the Fixed-line telephony/data segment, which offers local and long distance voice transmission and data communication services; the Mobile telephony segment, which offers primarily mobile voice, third generation (3G) data communication, and additional services, which include messaging services and interactivity, and the Other segment includes Internet service provider,
Will OIBR Get Buyers Even After The Recent Rally? Find Out Here
Array Biopharma Inc (NASDAQ:ARRY) opened the session at $5.16and closed the session at $5.19. The stock showed a positive performance of 0.58% in previous trading session. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways.
For How Long ARRY will fight for Profitability? Read This Trend Analysis report
Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) opened the session at $1.75 and closed the session at $1.86. The stock showed a positive performance of 5.68% in previous trading session. The beta of the stock remained 2.08. Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon Pharmaceuticals uses its gene knockout technologies and an integrated platform of medical technologies to study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets.
Why Should Investors Buy LXRX After The Recent Gain? Just Go Here and Find Out
Penn West Petroleum Ltd (USA) (NYSE:PWE) the stock advanced 0.35% and finished the session at $8.70. Traded with volume of 1.51 million shares in the prior session and the average volume of the stock remained 2.40 million shares. The beta of the stock remained 1.43. Penn West Petroleum Ltd. (Penn West), formerly Penn West Energy Trust, is a Canadian exploration and production company. Penn West is engaged in the business of acquiring, exploring, developing, exploiting and holding interests in petroleum and natural gas properties and related assets. Penn West participates in the exploration for, and the development and production of, oil and natural gas principally in western Canada. The majority of the Company’s proved plus probable reserves are located in Canada in Alberta, British Columbia, Saskatchewan, Manitoba and the Northwest Territories.
Will PWE Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)